Pulmonx (LUNG) Q2 2026 Earnings Call Transcript

Pulmonx reported Q2 2026 revenue of $22.8M (down 5% YoY) as China distributor shipments were suspended, while adjusted EBITDA loss narrowed 39% to $5.1M and net loss fell to $10.1M ($0.24/sh) from $15.2M ($0.38/sh). Gross margin improved to 78% (from 72%) and management reiterated full-year guidance of $90M–$92M revenue with ~76% gross margin, plus operating expense of $109M–$111M. The China registration certificate was renewed and shipments are expected to resume in early 2027; the company also restructured its credit facility to extend maturity to 2031 and access $20M additional capital tied to revenue milestones, targeting cash flow breakeven within the next few years.

Analysis

The near-term setup is better than the revenue line suggests: the real swing factor is not absolute sales this quarter, but whether the rep turnover reset has finally stabilized enough to convert installed centers into recurring utilization. That matters because Pulmonx is still operating with a high fixed-cost base; every incremental procedure should carry unusually high contribution margin, so a modest acceleration in U.S. activity can produce disproportionate EBITDA leverage. The flip side is that the company’s own commentary implies the market may be extrapolating too much from a single quarter of better expense discipline before the newer sales force has fully matured.

China is a second-order margin/catalyst issue, not just a revenue bridge. Resumption should help year-over-year growth, but the lower gross margin profile means headline growth may come with some mix dilution, so the stock could de-rate if investors model China as pure upside. The more important question is whether the international restart also reopens distributor inventory cycles; if so, there is a risk of a short-lived revenue pop followed by a digestion quarter, which would pressure sentiment into the first half of next year.

The contrarian view is that the move may be under-owned on balance-sheet risk but over-owned on narrative risk. The debt maturity extension and lower cash burn reduce dilution anxiety materially, yet the market may still be paying for AeriSeal option value that is too far out to matter for the next 12 months. Falsifiers are straightforward: if Q3 declines more than typical seasonality, if gross margin slips below the mid-70s once China restarts, or if center additions fail to translate into higher StratX volume by Q4, the growth inflection thesis should be questioned.

Key Decisions for Investors

• Watchlist, not immediate buy: wait for a post-earnings pullback and only initiate a starter long in LUNG if the stock trades down on Q3 seasonality concerns while holding above a cash/balance-sheet support level; the setup is better for 6-12 month holders than for traders.
• If you need exposure, use a small 6-9 month call spread in LUNG rather than common stock; the catalyst path is back-half 2026 sales ramp plus early-2027 China resumption, but execution risk is still high enough to cap upside in the near term.
• Pair trade idea: long LUNG / short a broader medtech ETF proxy if you want to isolate idiosyncratic operating leverage and China restart optionality; thesis breaks if quarterly revenue fails to reaccelerate sequentially into Q4.
• Set a thesis alert on LUNG gross margin: if management cannot hold at or above 75% after China shipments resume, the market should assume the current margin profile was mostly mix-driven rather than structural.
• No aggressive short: the refinancing and reduced cash burn make dilution risk less acute; shorts should wait for evidence that new rep productivity and center activation are not translating into StratX growth by the next two quarters.